meningococcal (groups A, C, Y, W) CRM197 conjugate vaccine
Trade name: Menveo
Vaccineapproved
Approved
Feb 19, 2010
Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin. — Wikipedia
Clinical trial activity
41 trials · 30 clinical orgs · 1 marketing orgs
Phase 1
3
Phase 2
24
Phase 3
22
Phase 4
8
Earliest trial started Jun 1, 2008 (NCT00661713)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
2010s
- Jan 1, 2010
Earliest Phase 3 Sponsor(trial)
- Feb 19, 2010
GlaxoSmithKline — Earliest FDA Approval
- Feb 19, 2010
GlaxoSmithKline — NDA Organization
- Jan 1, 2019
GlaxoSmithKline — Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Studied for
- Apnea · Phase 4
- Diphtheria · Phase 3
- Diphtheria-Tetanus-acellular Pertussis Vaccines · Phase 3
- Haemophilus Infections · Phase 1
- Haemophilus influenzae · Phase 2
- Haemophilus influenzae type b · Phase 3
- Healthy Volunteers · Phase 3
- Hepatitis B · Phase 3
- HIV · Phase 4
- Infant, Premature, Diseases · Phase 4
- Malaria · Phase 3
- Malaria, Falciparum · Phase 2
- Meninges · Phase 3
- Meningitis · Phase 4
- Meningitis, Meningococcal · Phase 4
- Meningococcal Infections · Phase 4
- Meningococcal Vaccines · Phase 2
- Papillomaviridae · Phase 4
- Pertussis Vaccine · Phase 3
- Pneumococcal Infections · Phase 3
- Pneumococcal Vaccines · Phase 3
- Poliomyelitis · Phase 3
- Respiratory Syncytial Virus Infections · Phase 1
- Sepsis · Phase 4
- Tetanus · Phase 3
- Vaccines · Phase 2
Mechanism of action
- Molecular identity unknownImmunity, active
Molecular identity unknown immunity, active
- Neisseria meningitidisImmunity, active
Neisseria meningitidis immunity, active
Approval history
- approvedFeb 19, 2010
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMeningococcal vaccine ↗
Also known as
- conjugated haemophilus influenzae type b vaccine
- haemophilus b conjugate vaccine diphteria crm197 protein conjugate
- hibtiter
- mcv4
- menveo
- omv nz
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07183371 | Phase 2 | Nov 30, 2025 | European and Developing Countries Clinical Trials Partnership (EDCTP), European Vaccine Initiative (EVI), Heidelberg, Germany, Government of Germany, Institut et Haute école de la Santé, La Source, University of Oxford |
| NCT07203755 | Phase 1 | Oct 22, 2025 | Government of China, Tianjin Cansino Biotechnology Inc |
| NCT07204457 | Phase 2/Phase 3 (Phase 3) | Oct 15, 2025 | BMI Korea, EyeGene Inc. |
| NCT06995430 | Phase 3 | Jul 7, 2025 | GlaxoSmithKline |
| NCT06700148 | Phase 3 | Dec 30, 2024 | Government of China, Tianjin Cansino Biotechnology Inc |
| NCT06436274 | Phase 4 | Sep 30, 2024 | Botswana Harvard Aids Institute, Government of Rwanda, Harvard University, Karolinska Institute, National Cancer Institute (NCI), University of the Witwatersrand, University of Washington |
| NCT06389513 | Phase 4 | Jun 12, 2024 | Tianjin Cansino Biotechnology Inc |
| NCT06226714 | Phase 3 | Mar 1, 2024 | Government of China, Tianjin Cansino Biotechnology Inc |
| NCT06131554 | Phase 3 | Dec 31, 2023 | Tianjin Cansino Biotechnology Inc |
| NCT06113198 | Phase 4 | Nov 15, 2023 | GlaxoSmithKline |
| NCT05935176 | Phase 4 | Sep 20, 2023 | Tianjin Cansino Biotechnology Inc |
| NCT06011200 | Phase 3 | Sep 16, 2023 | Tianjin Cansino Biotechnology Inc |
| NCT05739292 | Phase 1 | Feb 28, 2023 | EuBiologics Co.,Ltd |
| NCT04502693 | Phase 3 | Aug 14, 2020 | GlaxoSmithKline |
| NCT03636906 | Phase 1 | Apr 1, 2019 | GlaxoSmithKline |
| NCT03630705 | Phase 3 | Oct 31, 2018 | Sanofi-Aventis |
| NCT03673462 | Phase 3 | Sep 17, 2018 | Sanofi-Aventis |
| NCT03652610 | Phase 2 | Sep 10, 2018 | GlaxoSmithKline |
| NCT03530124 | Phase 4 | Jul 17, 2018 | Centers for Disease Control and Prevention (CDC), Duke University, University of Cincinnati, University of North Carolina at Chapel Hill |
| NCT03574389 | Phase 3 | Jun 23, 2018 | Pfizer |
Showing 20 of 41 trials
Page 1 / 3
Organizations
Research & Development (30)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 12 | 12 | 2 | 2008 |
| GlaxoSmithKline | For profit | 10 | 9 | 4 | 2012 |
| Tianjin Cansino Biotechnology Inc | For profit | 7 | 7 | 3 | 2023 |
| Government of China | Government | 3 | 0 | 2 | 2024 |
| Pfizer | For profit | 2 | 2 | 2 | 2011 |
| Sanofi-Aventis | For profit | 2 | 2 | 1 | 2018 |
| University of Oxford | Academic/Hospital | 2 | 2 | 2 | 2012 |
| BMI Korea | For profit | 1 | 0 | 1 | 2025 |
| Botswana Harvard Aids Institute | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Centers for Disease Control and Prevention (CDC) | Government | 1 | 0 | 1 | 2018 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| EuBiologics Co.,Ltd | For profit | 1 | 1 | 1 | 2023 |
| European and Developing Countries Clinical Trials Partnership (EDCTP) | Academic/Hospital | 1 | 0 | 1 | 2025 |
| European Vaccine Initiative (EVI), Heidelberg, Germany | Government | 1 | 0 | 1 | 2025 |
| EyeGene Inc. | For profit | 1 | 1 | 1 | 2025 |
| Government of Germany | Government | 1 | 0 | 1 | 2025 |
| Government of Rwanda | Government | 1 | 0 | 1 | 2024 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Institut et Haute école de la Santé, La Source | Academic/Hospital | 1 | 0 | 1 | 2025 |
| International Center for Diarrheal Disease Research | Academic/Hospital | 1 | 1 | 1 | 2018 |
30 organizations
Page 1 / 2
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| GlaxoSmithKline | For profit | NDA | Feb 19, 2010 |